|
|
|
1 | (82) |
|
|
|
2 | (2) |
|
|
|
2 | (1) |
|
|
|
2 | (1) |
|
|
|
3 | (1) |
|
|
|
3 | (1) |
|
Consolidation---General Recognition |
|
|
3 | (1) |
|
|
|
3 | (1) |
|
|
|
4 | (4) |
|
Drug and Active Principle |
|
|
4 | (1) |
|
The Aims of Isolating Active Principles |
|
|
4 | (2) |
|
European Plants as Sources of Effective Medicines |
|
|
6 | (2) |
|
|
|
8 | (4) |
|
Congeneric Drugs and Name Diversity |
|
|
10 | (2) |
|
|
|
12 | (8) |
|
|
|
12 | (2) |
|
Drug Administration by Inhalation |
|
|
14 | (2) |
|
|
|
16 | (1) |
|
|
|
16 | (1) |
|
Dermatological Agents as Vehicles (B) |
|
|
16 | (2) |
|
From Application to Distribution in the Body |
|
|
18 | (2) |
|
|
|
20 | (2) |
|
Potential Targets of Drug Action |
|
|
20 | (2) |
|
|
|
22 | (10) |
|
External Barriers of the Body |
|
|
22 | (2) |
|
|
|
24 | (2) |
|
|
|
26 | (2) |
|
Possible Modes of Drug Distribution |
|
|
28 | (2) |
|
Binding to Plasma Proteins |
|
|
30 | (2) |
|
|
|
32 | (12) |
|
The Liver as an Excretory Organ |
|
|
32 | (2) |
|
Biotransformation of Drugs |
|
|
34 | (4) |
|
Drug Metabolism by Cytochrome P450 |
|
|
38 | (2) |
|
The Kidney as an Excretory Organ |
|
|
40 | (2) |
|
|
|
42 | (2) |
|
|
|
44 | (8) |
|
Drug Concentration in the Body as a Function of Time---First Order (Exponential) Rate Processes |
|
|
44 | (2) |
|
Time Course of Drug Concentration in Plasma |
|
|
46 | (2) |
|
Time Course of Drug Plasma Levels during Repeated Dosing (A) |
|
|
48 | (1) |
|
Time Course of Drug Plasma Levels during Irregular Intake (B) |
|
|
48 | (2) |
|
Accumulation: Dose, Dose Interval, and Plasma Level Fluctuation (A) |
|
|
50 | (1) |
|
Change in Elimination Characteristics during Drug Therapy (B) |
|
|
50 | (2) |
|
Quantification of Drug Action |
|
|
52 | (4) |
|
Dose--Response Relationship |
|
|
52 | (2) |
|
Concentration--Effect Relationship (A) |
|
|
54 | (1) |
|
Concentration--Effect Curves (B) |
|
|
54 | (2) |
|
Drug--Receptor Interaction |
|
|
56 | (14) |
|
Concentration--Binding Curves |
|
|
56 | (2) |
|
|
|
58 | (2) |
|
|
|
58 | (1) |
|
|
|
58 | (2) |
|
|
|
60 | (1) |
|
Models of the Molecular Mechanism of Agonist/Antagonist Action (A) |
|
|
60 | (1) |
|
Other Forms of Antagonism |
|
|
60 | (2) |
|
Enantioselectivity of Drug Action |
|
|
62 | (2) |
|
|
|
64 | (2) |
|
Mode of Operation of G-Protein-coupled Receptors |
|
|
66 | (2) |
|
Time Course of Plasma Concentration and Effect |
|
|
68 | (2) |
|
|
|
70 | (8) |
|
Undesirable Drug Effects, Side Effects |
|
|
70 | (1) |
|
Causes of Adverse Effects |
|
|
70 | (2) |
|
|
|
72 | (2) |
|
|
|
74 | (2) |
|
Drug Toxicity in Pregnancy and Lactation |
|
|
76 | (2) |
|
Genetic Variation of Drug Effects |
|
|
78 | (2) |
|
|
|
78 | (2) |
|
|
|
80 | (3) |
|
|
|
80 | (3) |
|
|
|
83 | (230) |
|
Drugs Acting on the Sympathetic Nervous System |
|
|
84 | (18) |
|
Sympathetic Nervous System |
|
|
84 | (2) |
|
Structure of the Sympathetic Nervous System |
|
|
86 | (1) |
|
|
|
86 | (2) |
|
Adrenoceptor Subtypes and Catecholamine Actions |
|
|
88 | (1) |
|
|
|
88 | (1) |
|
|
|
88 | (1) |
|
|
|
88 | (2) |
|
Structure--Activity Relationships of Sympathomimetics |
|
|
90 | (2) |
|
Indirect Sympathomimetics |
|
|
92 | (2) |
|
α-Sympathomimetics, α-Sympatholytics |
|
|
94 | (2) |
|
β-Sympatholytics (β-Blockers) |
|
|
96 | (2) |
|
|
|
98 | (2) |
|
|
|
100 | (2) |
|
Drugs Acting on the Parasympathetic Nervous System |
|
|
102 | (10) |
|
Parasympathetic Nervous System |
|
|
102 | (2) |
|
|
|
104 | (2) |
|
|
|
106 | (2) |
|
|
|
108 | (4) |
|
|
|
112 | (4) |
|
|
|
112 | (1) |
|
Localization of Nicotinic ACh Receptors |
|
|
112 | (1) |
|
Effects of Nicotine on Body Function |
|
|
112 | (1) |
|
Aids for Smoking Cessation |
|
|
112 | (2) |
|
Consequences of Tobacco Smoking |
|
|
114 | (2) |
|
|
|
116 | (6) |
|
|
|
116 | (2) |
|
Histamine Effects and Their Pharmacological Properties |
|
|
118 | (2) |
|
|
|
120 | (2) |
|
|
|
122 | (6) |
|
|
|
122 | (2) |
|
|
|
124 | (2) |
|
|
|
126 | (1) |
|
Dihydropyridine Derivatives |
|
|
126 | (1) |
|
Verapamil and Other Catamphiphilic Ca2+ Antagonists |
|
|
126 | (2) |
|
Inhibitors of the Renin--Angiotensin--Aldosterone System |
|
|
128 | (2) |
|
|
|
128 | (2) |
|
Drugs Acting on Smooth Muscle |
|
|
130 | (2) |
|
Drugs Used to Influence Smooth Muscle Organs |
|
|
130 | (2) |
|
|
|
132 | (8) |
|
|
|
134 | (2) |
|
|
|
136 | (2) |
|
Drugs for Selective Control of Sinoatrial and AV Nodes |
|
|
136 | (1) |
|
Nonspecific Drug Actions on Impulse Generation and Propagation |
|
|
136 | (2) |
|
Electrophysiological Actions of Antiarrhythmics of the Na+-Channel Blocking Type |
|
|
138 | (2) |
|
|
|
140 | (4) |
|
Drugs for the Treatment of Anemias |
|
|
140 | (2) |
|
|
|
140 | (1) |
|
|
|
140 | (1) |
|
|
|
140 | (2) |
|
|
|
142 | (2) |
|
|
|
144 | (12) |
|
Prophylaxis and Therapy of Thromboses |
|
|
144 | (2) |
|
Vitamin K Antagonists and Vitamin K |
|
|
146 | (1) |
|
Possibilities for Interference (B) |
|
|
146 | (2) |
|
|
|
148 | (1) |
|
Hirudin and Derivatives (B) |
|
|
148 | (2) |
|
|
|
150 | (2) |
|
Intra-arterial Thrombus Formation (A) |
|
|
152 | (1) |
|
Formation, Activation, and Aggregation of Platelets (B) |
|
|
152 | (2) |
|
Inhibitors of Platelet Aggregation (A) |
|
|
154 | (1) |
|
Presystemic Effect of ASA |
|
|
154 | (2) |
|
|
|
156 | (2) |
|
Drugs Used in Hyperlipoproteinemias |
|
|
158 | (4) |
|
|
|
158 | (4) |
|
|
|
162 | (8) |
|
|
|
162 | (2) |
|
NaCl Reabsorption in the Kidney (A) |
|
|
164 | (1) |
|
|
|
164 | (1) |
|
|
|
164 | (2) |
|
Diuretics of the Sulfonamide Type |
|
|
166 | (2) |
|
Potassium-sparing Diuretics and Vasopressin |
|
|
168 | (1) |
|
Potassium-sparing Diuretics (A) |
|
|
168 | (1) |
|
Vasopressin and Derivatives (B) |
|
|
168 | (2) |
|
Drugs for the Treatment of Peptic Ulcers |
|
|
170 | (4) |
|
Drugs for Gastric and Duodenal Ulcers |
|
|
170 | (4) |
|
Lowering of Acid Concentration |
|
|
170 | (2) |
|
|
|
172 | (1) |
|
Eradication of Helicobacter pylori (C) |
|
|
172 | (2) |
|
|
|
174 | (6) |
|
|
|
174 | (2) |
|
|
|
176 | (2) |
|
Small-Bowel Irritant Purgative |
|
|
178 | (1) |
|
Large-Bowel Irritant Purgatives |
|
|
178 | (1) |
|
|
|
178 | (2) |
|
|
|
180 | (2) |
|
|
|
180 | (2) |
|
Drugs Acting on the Motor System |
|
|
182 | (12) |
|
Drugs Affecting Motor Function |
|
|
182 | (2) |
|
|
|
184 | (1) |
|
Nondepolarizing Muscle Relaxants |
|
|
184 | (2) |
|
Depolarizing Muscle Relaxants |
|
|
186 | (2) |
|
|
|
188 | (2) |
|
|
|
190 | (4) |
|
Drugs for the Suppression of Pain |
|
|
194 | (2) |
|
Pain Mechanisms and Pathways |
|
|
194 | (2) |
|
|
|
196 | (4) |
|
|
|
196 | (2) |
|
Antipyretic Analgesics vs. NSAIDs |
|
|
198 | (1) |
|
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) |
|
|
198 | (2) |
|
Nonsteroidal Anti-inflammatory Drugs |
|
|
200 | (2) |
|
Cyclooxygenase (COX) Inhibitors |
|
|
200 | (2) |
|
|
|
202 | (6) |
|
|
|
208 | (6) |
|
Opioid Analgesics--Morphine Type |
|
|
208 | (6) |
|
|
|
214 | (6) |
|
General Anesthesia and General Anesthetic Drugs |
|
|
214 | (2) |
|
|
|
216 | (2) |
|
|
|
218 | (2) |
|
|
|
220 | (18) |
|
|
|
220 | (2) |
|
|
|
222 | (2) |
|
Benzodiazepine Antagonist |
|
|
222 | (2) |
|
Pharmacokinetics of Benzodiazepines |
|
|
224 | (2) |
|
Therapy of Depressive Illness |
|
|
226 | (4) |
|
|
|
230 | (2) |
|
|
|
232 | (4) |
|
|
|
232 | (4) |
|
Psychotomimetics (Psychedelics, Hallucinogens) |
|
|
236 | (2) |
|
|
|
238 | (30) |
|
Hypothalamic and Hypophyseal Hormones |
|
|
238 | (2) |
|
|
|
240 | (2) |
|
Hyperthyroidism and Antithyroid Drugs |
|
|
242 | (2) |
|
|
|
244 | (1) |
|
|
|
244 | (1) |
|
Pharmacodynamic Therapy with Glucocorticoids (A) |
|
|
244 | (4) |
|
Androgens, Anabolic Steroids, Antiandrogens |
|
|
248 | (2) |
|
|
|
248 | (2) |
|
Follicular Growth and Ovulation, Estrogen and Progestin Production |
|
|
250 | (2) |
|
|
|
252 | (2) |
|
Antiestrogen and Antiprogestin Active Principles |
|
|
254 | (2) |
|
|
|
256 | (2) |
|
|
|
258 | (2) |
|
Variations in Dosage Form |
|
|
258 | (1) |
|
Variation in Amino Acid Sequence |
|
|
258 | (2) |
|
Treatment of Insulin-dependent Diabetes Mellitus |
|
|
260 | (2) |
|
|
|
260 | (2) |
|
Treatment of Maturity-Onset (Type II) Diabetes Mellitus |
|
|
262 | (2) |
|
|
|
264 | (2) |
|
Drugs for Maintaining Calcium Homeostasis |
|
|
266 | (2) |
|
|
|
268 | (16) |
|
Drugs for Treating Bacterial Infections |
|
|
268 | (2) |
|
Inhibitors of Cell Wall Synthesis |
|
|
270 | (4) |
|
Inhibitors of Tetrahydrofolate Synthesis |
|
|
274 | (2) |
|
Inhibitors of DNA Function |
|
|
276 | (2) |
|
Inhibitors of Protein Synthesis |
|
|
278 | (4) |
|
Drugs for Treating Mycobacterial Infections |
|
|
282 | (2) |
|
|
|
282 | (1) |
|
|
|
282 | (2) |
|
|
|
284 | (2) |
|
Drugs Used in the Treatment of Fungal Infections |
|
|
284 | (2) |
|
|
|
286 | (6) |
|
Chemotherapy of Viral Infections |
|
|
286 | (4) |
|
Drugs for the Treatment of AIDS |
|
|
290 | (2) |
|
Inhibitors of Reverse Transcriptase--Nucleoside Agents |
|
|
290 | (1) |
|
|
|
290 | (1) |
|
|
|
290 | (1) |
|
|
|
290 | (2) |
|
|
|
292 | (6) |
|
Drugs for Treating Endoparasitic and Ectoparasitic Infestations |
|
|
292 | (2) |
|
|
|
294 | (2) |
|
|
|
296 | (2) |
|
|
|
298 | (6) |
|
Chemotherapy of Malignant Tumors |
|
|
298 | (4) |
|
Targeting of Antineoplastic Drug Action (A) |
|
|
302 | (1) |
|
Mechanisms of Resistance to Cytostatics (B) |
|
|
302 | (2) |
|
|
|
304 | (4) |
|
Inhibition of Immune Responses |
|
|
304 | (4) |
|
|
|
308 | (5) |
|
Antidotes and Treatment of Poisonings |
|
|
308 | (5) |
|
Therapy of Selected Diseases |
|
|
313 | (36) |
|
|
|
314 | (2) |
|
|
|
316 | (2) |
|
|
|
318 | (2) |
|
Acute Coronary Syndrome--Myocardial Infarction |
|
|
320 | (2) |
|
|
|
322 | (2) |
|
|
|
324 | (2) |
|
|
|
326 | (2) |
|
Obesity--Sequelae and Therapeutic Approaches |
|
|
328 | (2) |
|
|
|
330 | (2) |
|
|
|
332 | (2) |
|
|
|
334 | (2) |
|
|
|
336 | (2) |
|
Atopy and Antiallergic Therapy |
|
|
338 | (2) |
|
|
|
340 | (2) |
|
|
|
342 | (2) |
|
|
|
344 | (2) |
|
Local Treatment of Glaucoma |
|
|
346 | (3) |
|
|
|
349 | (2) |
|
|
|
351 | (30) |
|
|
|
352 | (17) |
|
|
|
369 | (12) |
| Subject Index |
|
381 | |
